Welcome to our dedicated page for PSYENCE BIOMEDICAL LTD. SEC filings (Ticker: PBMWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PSYENCE BIOMEDICAL LTD.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PSYENCE BIOMEDICAL LTD.'s regulatory disclosures and financial reporting.
Psyence Biomedical Ltd. (PBM) announced the formation of Texas Ibogaine Research Corporation (TIRC), a Texas-based subsidiary created to coordinate its U.S. ibogaine development activities, including pharmaceutical-grade supply, regulatory engagement and potential clinical development. TIRC is intended to be the dedicated U.S. vehicle for regulated ibogaine development.
Subject to definitive licensing arrangements, TIRC is positioned to hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, in which Psyence BioMed holds an ownership interest, and will be financed by Psyence BioMed. Jody Aufrichtig will serve as Chief Executive Officer of both Psyence BioMed and TIRC, with Dr. John Thorne as project lead. The company highlights that ibogaine remains a controlled substance and is not approved for therapeutic use, and it outlines regulatory, financing and policy risks that could affect the planned activities.
Psyence Biomedical Ltd. presents an August 2026 investor update describing its clinical-stage focus on nature-derived psychedelic therapeutics for mental health in cancer palliative care, Alcohol Use Disorder, Substance Use Disorder and longevity science. The company highlights having no debt, a strong cash position and two low-cost financing mechanisms, and a vertically integrated platform via a strategic equity stake and supply partnership with PsyLabs for GMP-compliant psilocybin, ibogaine, DMT and mescaline.
The presentation details an Australian Phase IIb trial of NPX-5, a botanical psilocybin, for Adjustment Disorder associated with cancer in the palliative care setting, with 87 patients across three dose arms and a HAM-A primary endpoint at ten weeks, following HREC ethics approval, first patient dosing and FDA Pre-IND feedback. Psyence BioMed outlines an anticipated pathway with topline results planned in H1 2027 and future regulatory interactions, and emphasizes intellectual property efforts and potential data exclusivity. It also describes its ibogaine program, notes a $23.3B projected global palliative care market by 2032 and references a recent U.S. executive order committing $50 million to ibogaine research, framing a supportive external environment for its pipeline.
Psyence Biomedical Ltd. files its annual Form 20-F as a clinical-stage biotechnology company focused on psilocybin-based therapies. The report emphasizes that the company has never generated revenue and recorded net profit/(loss) of ($6.89 million), $1 million and ($50.96 million) for the years ended March 31, 2026, 2025 and 2024, respectively.
Psyence discloses it is financing operations through equity and convertible debt, expects significant losses for the foreseeable future, and will require substantial additional funding to advance its Phase IIb study in Australia and potential Phase III program. As of March 31, 2026, cash, cash equivalents and restricted cash totaled USD$7,491,954, which management expects will fund operations beyond 12 months from the filing date.
The company outlines extensive risks, including clinical, regulatory and supply-chain uncertainty, dependence on key partners and licensed IP, U.S. Schedule I status for psilocybin and ibogaine, intense competition in psychedelic therapies, evolving governmental policy, and the possibility that future research, regulation or public perception could materially harm demand for its prospective products.
PSYENCE BIOMEDICAL LTD. amendment reports that Jeffrey David Weiner beneficially owns 59,750 common shares, equal to 2.61% of the class. The filing states this percentage is based on 2,293,307 total outstanding shares reported by the company. The form is signed on 06/09/2026 and is labeled as an amendment to prior ownership disclosure.
Psyence Biomedical Ltd. filed a Form 6-K as a foreign private issuer to report a technical change to its 2023 Equity Incentive Plan. On May 4, 2026, the board approved an amendment and restatement of the plan to correct a typographical error in Section 4(b).
The updated plan, referred to as the First Amended and Restated Equity Incentive Plan, is provided in full as Exhibit 10.1. The filing does not describe any change to plan substance beyond this correction and is signed by the company’s Chief Financial Officer, Warwick Corden-Lloyd.
Psyence Labs Ltd. has filed a Schedule 13D reporting a new major ownership position in Psyence Biomedical Ltd.. Psyence Labs acquired 1,146,159 Common Shares in a share-for-share exchange valued at US$5,000,000, giving it beneficial ownership of about 30.05% of Psyence Biomedical’s outstanding Common Shares.
The Issuer issued these shares in exchange for 2,900 ordinary shares of Psyence Labs, with no cash paid by either party. Psyence Labs describes the holdings as an investment and may, depending on market and company conditions, buy more securities, sell some or all of its stake, or engage in hedging or similar transactions.
Psyence BioMed has begun dosing patients in a Phase IIb clinical trial of NPX-5, a 25mg nature-derived psilocybin candidate, for Adjustment Disorder in cancer patients in a palliative care setting across clinical sites in Australia.
The randomized, double-blind, three-arm study is designed to evaluate both the safety and therapeutic potential of NPX-5 within a structured, therapy-supported treatment model. This is the first active clinical evaluation of NPX-5 and marks a shift toward systematic human data generation within the company’s Australian clinical network.
The program is positioned as a core element of Psyence BioMed’s vertically integrated platform, which combines GMP-compliant manufacturing, clinical development, and global supply capabilities, with the aim of addressing significant unmet mental health needs using nature-derived psychedelic-based therapeutics.
Psyence Biomedical Ltd. updated its common stock purchase agreement with White Lion Capital to add a new intraday share sale option. During the commitment period, Psyence can issue an Intraday Purchase Notice requiring White Lion to buy common shares up to 5% of the Average Daily Trading Volume per notice.
The purchase price is the lowest traded price during a one-hour valuation window after White Lion’s written acceptance, subject to a floor price set in each notice. White Lion must consent within 15 minutes and settle within two business days. In connection with the amendment, White Lion will pay Psyence a $22,000 legal document preparation fee.
Psyence Biomedical Ltd. filed a Form 6-K highlighting a press release that welcomes anticipated U.S. executive action to further evaluate the safety and therapeutic potential of ibogaine. The company notes that ibogaine is being studied for difficult conditions such as PTSD, addiction, and other serious neurological and mental health disorders.
Psyence BioMed emphasizes its strategic investment in PsyLabs, describing a leading position in GMP-compliant ibogaine manufacturing and an ethically sourced ibogaine supply chain within the compound’s native African ecosystem. The company presents its vertically integrated platform—ethical sourcing, GMP manufacturing, and clinical development—as support for future regulated ibogaine research, while cautioning that any U.S. executive order is not assured and may not affect its operations.
Psyence Biomedical Ltd. describes several corporate developments. The company’s subsidiary agreed to lend US$251,110 to Curiosum Ltd. at Royal Bank prime plus 1%, maturing three months after the February 9, 2026 loan agreement, to fund Curiosum’s purchase of 50,220 Psyence Biomedical shares from the KAOS Group under a prior settlement.
The company also completed a share-for-share exchange tied to Psyence Labs Ltd.’s exercised put option. Psyence Labs issued 2,900 of its shares valued at US$5,000,000, and Psyence Biomedical issued 1,146,159 common shares based on a 30‑day VWAP, with no cash changing hands. Following this issuance, Psyence Labs beneficially owns about 49.98% of Psyence Biomedical’s common shares, compared with 1,147,148 shares outstanding before the transaction.
On the governance side, director Seth Feuerstein resigned, stating no disagreement with the company. The board appointed Sashank Pillay as an independent director and committee member, citing his experience in cultivation, production and regulated substance operations.